- Home
- NGNE vs OTLY Comparison
NGNE vs OTLY Comparison
Compare NGNE & OTLY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NGNE
- OTLY
- Stock Information
- Founded
- NGNE 2003
- OTLY 1994
- Country
- NGNE United States
- OTLY Sweden
- Employees
- NGNE N/A
- OTLY N/A
- Industry
- NGNE Biotechnology: Pharmaceutical Preparations
- OTLY Packaged Foods
- Sector
- NGNE Health Care
- OTLY Consumer Staples
- Exchange
- NGNE Nasdaq
- OTLY Nasdaq
- Market Cap
- NGNE 325.3M
- OTLY 303.5M
- IPO Year
- NGNE N/A
- OTLY 2021
- Fundamental
- Price
- NGNE $18.48
- OTLY $17.59
- Analyst Decision
- NGNE Strong Buy
- OTLY Buy
- Analyst Count
- NGNE 7
- OTLY 5
- Target Price
- NGNE $41.86
- OTLY $19.25
- AVG Volume (30 Days)
- NGNE 110.1K
- OTLY 202.0K
- Earning Date
- NGNE 08-11-2025
- OTLY 07-23-2025
- Dividend Yield
- NGNE N/A
- OTLY N/A
- EPS Growth
- NGNE N/A
- OTLY N/A
- EPS
- NGNE N/A
- OTLY N/A
- Revenue
- NGNE N/A
- OTLY $828,200,000.00
- Revenue This Year
- NGNE N/A
- OTLY $3.83
- Revenue Next Year
- NGNE N/A
- OTLY $4.51
- P/E Ratio
- NGNE N/A
- OTLY N/A
- Revenue Growth
- NGNE N/A
- OTLY 4.43
- 52 Week Low
- NGNE $6.88
- OTLY $6.00
- 52 Week High
- NGNE $74.49
- OTLY $20.80
- Technical
- Relative Strength Index (RSI)
- NGNE 35.93
- OTLY 56.82
- Support Level
- NGNE $19.59
- OTLY $17.75
- Resistance Level
- NGNE $20.46
- OTLY $18.84
- Average True Range (ATR)
- NGNE 1.23
- OTLY 0.93
- MACD
- NGNE -0.20
- OTLY -0.06
- Stochastic Oscillator
- NGNE 13.37
- OTLY 52.28
About NGNE Neurogene Inc.
Neurogene Inc is a clinical-stage biotechnology company committed to overcoming the limitations of neurological diseases into treatable conditions, by harnessing its proprietary transgene regulation technology, EXACTTM (Expression Attenuation via Construct Tuning). It is building a differentiated product portfolio of genetic medicines for rare neurological diseases with high unmet needs. The drug candidates in the company's product pipeline include NGN-401, which is in development for the treatment of Rett syndrome, using its EXACT platform, and NGN-101, a non-EXACT, conventional gene therapy development candidate for the treatment of CLN5 Batten disease, designed to deliver the CLN5 gene and packaged in an AAV9 capsid.
About OTLY Oatly Group AB
Oatly Group AB is engaged in the food and drinks industry. Some of its products include Oat Drink, Chilled Oat Drink, Oatgurt, Creamy Oat, and Icecreams, among others. It caters to Sweden, Germany, the United Kingdom, Netherlands, North America, Finland, and Other markets. The company generates revenue from the EMEA, Americas, and Asia regions, with the majority of revenue generated from the EMEA region.